FULPHILA Q Code: Q5108

Drug & Product Overview

HCPCS Descriptor Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg

HCPCS Added Date October 1, 2018

Manufacturer Biocon Biologics Inc

Route of Administration Subcutaneous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection

About FULPHILA

Fulphila is a medication aligned to the HCPCS Q Code: Q5108 for billing, pricing, and reimbursement purposes in the United States. This Oncology Colony Stimulating Factor medication is administered via the subcutaneous route and manufactured by Biocon Biologics Inc.

According to CMS Drug Use Information: Pegfilgrastim is a man-made version of a certain natural substance made by your body. It is used to help your body make more white blood cells. White blood cells are important to help you fight off infections. Pegfilgrastim is given to people whose ability to make white blood cells is reduced due to chemotherapy. Some brands may also be used to increase white blood cells after exposure to large amounts of radiation. This monograph is about the following pegfilgrastim products: pegfilgrastim, pegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, pegfilgrastim-fpgk, pegfilgrastim-jmdb, and pegfilgrastim-pbbk.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
67457-0833-06	Fulphila	Viatris - Greenstone LLC	12	6 MG / 0.6 ML
83257-0005-41	Fulphila	Biocon Biologics Inc.	12	6 MG / 0.6 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

FULPHILA Pricing & Reimbursement

Q5108 Private Payer Reimbursement

$103.16 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

Pegfilgrastim Biosimilar Information:

FULPHILA Approval Date: June 4, 2018

Product Name	HCPCS Code	Active Ingredient	BLA Type
Neulasta	J2506	Pegfilgrastim	351(a) Originator Product
Fulphila	Q5108	Pegfilgrastim	351(k) Biosimilar
Udenyca	Q5111	Pegfilgrastim	351(k) Biosimilar
Ziextenzo	Q5120	Pegfilgrastim	351(k) Biosimilar
Nyvepria	Q5122	Pegfilgrastim	351(k) Biosimilar
Fylnetra	Q5130	Pegfilgrastim	351(k) Biosimilar
Stimufend	Q5127	Pegfilgrastim	351(k) Biosimilar
Armlupeg	Q5169	Pegfilgrastim	351(k) Biosimilar
Ennumo	N/A	Pegfilgrastim	351(k) Biosimilar

FULPHILA Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 12.59%

Avg. Days to File 7.0days

Avg. Days to Pay 22.0days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore Q5108 claims analytics on FocalPoint →

FULPHILA CPT Administration Codes

CPT Code	Description
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular

JW / JZ modifiers apply

CMS has identified Fulphila (Q5108) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

FULPHILA Medically Unlikely Edits (MUE)

The most billing units of Q5108 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 0.5 mg.

Practitioner Office & Hospital Outpatient

12 units / day

= 6 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

FULPHILA Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

non-myeloid malignancies receiving myelosuppressive anti-cancer drugs

Drug Class

Granulocyte Colony-Stimulating Factor [CS]Increased Myeloid Cell Production [PE]Leukocyte Growth Factor [EPC]

Frequently Asked Questions

Is there an available Fulphila billing and coding guide?

Billing and coding information for FULPHILA can be found through Biocon Biologics Inc. Visit Here →

Are there any available Fulphila patient assistance programs?

Our team has not identified a manufacturer-published source of patient assistance information for FULPHILA.

Where can I find Fulphila prescribing information?

FULPHILA prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date. Visit Here →

Where can I find Fulphila side effect information?

Our team has not yet identified a source of side effects information for FULPHILA. Please check back in a few weeks.

Does billing FULPHILA require JZ/JW wastage modifiers?

CMS has identified FULPHILA(Q5108) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.